Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors Meeting Abstract
| Authors: | Sharma, M.; Carvajal, R. D.; Hanna, G. J.; Li, B. T.; Moore, K. N.; Pegram, M. D.; Rasco, D. W.; Spira, A. I.; Alonso, M.; Fang, L.; Husain, A.; Perez, E. A.; Dumbrava, E. E. |
| Abstract Title: | Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120601071 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.2549 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2549 -- Source: Wos |
